GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
Gold Price Today : Gold prices drop by Rs 6,500/10 gm from record high level, silver at Rs 96,287/kg
13/05/2025
Pharma stocks rally up to 4%, but will Trump order really have minimal impact ?
13/05/2025
Defence stocks rally up to 4% after Modi's call for ‘Made in India’ military gear, battle-tested arms shine in Operation (...)
13/05/2025
Q4 results today : Tata Motors, Airtel among 83 companies to announce earnings on Tuesday
13/05/2025
Foreign banks dump $3 billion worth g-secs amid India-Pak tensions
13/05/2025
Ant Financial to sell shares worth Rs 2,200 crore in Paytm parent
13/05/2025
